Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Slides:

Advertisements

Similar presentations

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Advertisements

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

MACE rate among CAD severity groups (total 0

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

(A–C) Sequential angiographic images demonstrating placement of the wire, using the retrograde technique in the LV cavity (A), followed by balloon placement.

Fig. 2. Evidence-based medication prescriptions

Nat. Rev. Cardiol. doi: /nrcardio

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Masashi Maeda et al. Heart Asia 2013;5:7-14

The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.

HOMA calculations where glucose is mmol/L and insulin is mU/L

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet.

Comparison of CMR and echocardiography in aortic regurgitation.

Cumulative survival without events during 1 year in patients with preserved systolic function (left ventricular ejection fraction (LVEF) >40%) and with.

The proportion of patients confronted with a cardiovascular risk factor (CVRF) they were previously unaware of, referring to the instrument based tests.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Toray microarray analysis of the four groups of patients (A) and in patients with calcium score >100 (B). Toray microarray analysis of the four groups.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome.

UK paediatric cardiac surgery mortality rate by year for all cases and total number of procedures performed between 2000 and 2009/2010. UK paediatric cardiac.

(A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. (A) Absolute and (B) change from.

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.

Cost of healthcare and sick leave before and after heart valve surgery (€). Cost of healthcare and sick leave before and after heart valve surgery (€).

Flow chart showing reinterventions by type in patients with anomalous origin of coronary artery from the pulmonary artery patients, divided into early.

Cumulative survival without events during the first 42 days of treatment with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril (n=351)

Different behaviours between group 1 and group 2 patients of the mean and SD of Δ for low frequency (LF), high frequency (HF) and total power (TP) calculated.

Kaplan–Meyer survival curve of 1313 patients following primary PCI

ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide.

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

(A) Absolute and B) change from baseline in 6 min walk distance over time for patients on bosentan monotherapy by Down syndrome status. (A) Absolute and.

The 6MWT results showing improvement from baseline at 1, 6 and 12 months in patients receiving an implant (mean±SE of mean). The 6MWT results showing improvement.

Simpson's biplane ejection fraction (A), and two-dimensional speckle-tracking global longitudinal strain (B) in patients receiving clozapine treatment,

Bland-Altman plots for intra and inter observer variability for the assessment of total Agatston score for patients with a calcium score less than 1000.

Ejection fraction preoperatively and at follow-up in conventional (C) and no-touch (NT) groups. Ejection fraction preoperatively and at follow-up in conventional.

Analysis of receiver operating characteristic of fetuin-A.

Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate.

Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.

Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta.

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus.

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Results of comparisons of treatments in the network.

Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A)

Decision tree (using the CHAID algorithm) for predicting participation in a cardiac prevention and rehabilitation programme (CPRP) among 420 Jewish and.

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Forest plot of all-cause mortality (ACM) in CRT patient with AF comparing atrioventricular junction ablation (AVJA) versus no AVJA. AF, atrial fibrillation;

The QT interval responses to different pacing rates in a patient in group I. The pacing rate was decreased from 110 to 50 beats/min and the QT interval.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

(A) Kaplan-Meier estimates of MACCE in patients with a non-culprit MaxLCBI4mm ≥400 and MaxLCBI4mm

Comparison of heart failure admissions rates per annum (recorded hospital admissions/ population at risk) in western developed countries 1978 to.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB) and the number of patients who received no treatment or treatment with ACEi, BB or both from 2010 to 2013. Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB) and the number of patients who received no treatment or treatment with ACEi, BB or both from 2010 to 2013. Simon Walker et al. Open Heart 2017;4:e000726 ©2017 by British Cardiovascular Society